Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 4.950-5.350 for the period, compared to the consensus EPS estimate of 4.690. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Halozyme Therapeutics Stock Up 5.0 %

Shares of HALO opened at $53.76 on Thursday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The stock has a market capitalization of $6.84 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24. The stock has a fifty day moving average of $50.10 and a 200-day moving average of $54.00.

Analyst Ratings Changes

HALO has been the topic of several research reports. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $58.00 to $62.00 in a report on Monday, October 7th. JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $61.11.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.